DEF: Precision BioSciences Sets Date for 2025 Annual Stockholder Meeting, Outlines Key Proposals
Proxy Statement
Precision BioSciences will hold its 2025 annual meeting of stockholders on May 28, 2025, via a virtual webcast.
Summary
- Precision BioSciences will hold its 2025 annual meeting of stockholders on May 28, 2025, at 11:00 a.m. Eastern Time, as a virtual meeting via live webcast.
- Stockholders of record as of April 8, 2025, are entitled to vote.
- The meeting will address the election of Kevin J. Buehler and Shari Lisa Pir as Class III directors, ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2025, an advisory vote on executive compensation (say-on-pay), an advisory vote on the frequency of future say-on-pay votes, and approval of an amendment to the Certificate of Incorporation regarding officer exculpation.
- The Board recommends voting for the director nominees, for the ratification of the accounting firm, for the approval of executive compensation, for holding say-on-pay votes every year, and for the approval of the amendment to the Certificate of Incorporation.
- In 2024, Audit fees were $863,000, tax fees were $41,000 and all other fees were $6,000.
- The company's corporate goal attainment for 2024 was 105%.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, which is generally neutral in tone. The Board's recommendations are clear and supportive of management, suggesting a positive outlook on the company's direction.
Positives
- The Board recommends holding advisory votes on executive compensation annually, which they believe will facilitate the highest level of accountability to stockholders.
- The company's corporate goal attainment for 2024 was 105%.
Risks
- Failure to approve the amendment to the Certificate of Incorporation regarding officer exculpation could adversely impact the company's ability to attract and retain highly qualified officer candidates.
- The company acknowledges that the use of the term 'compensation actually paid' is required by the SEC's rules and, as a result of the calculation methodology required by the SEC, such amounts differ from total compensation reported in the Summary Compensation Table for the applicable fiscal year actually earned, realized or received by the NEOs.
Future Outlook
The company intends to file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for its 2025 Annual Meeting.
Management Comments
- Kevin J. Buehler, Chair of the Board, expressed appreciation for stockholders' continued support.
- The Board believes that annual votes on executive compensation will facilitate the highest level of accountability to stockholders.
Industry Context
The document reflects standard corporate governance practices for publicly traded companies, including the solicitation of proxies, the election of directors, and the ratification of the appointment of an independent registered public accounting firm.
Comparison to Industry Standards
- The proxy statement's structure and content align with those of similar biotechnology companies, including sections on executive compensation, corporate governance, and related-party transactions.
- The director compensation policy, including annual fees and equity grants, appears to be consistent with industry benchmarks for companies of similar size and stage of development.
- The company's engagement of Aon as an independent compensation consultant is a common practice among publicly traded companies to ensure that executive compensation is aligned with performance and market standards.
Stakeholder Impact
- The outcome of the votes on the proposals will impact the composition of the Board of Directors, the selection of the independent registered public accounting firm, and the company's approach to executive compensation.
- Approval of the amendment to the Certificate of Incorporation regarding officer exculpation could affect the company's ability to attract and retain key executive talent.
Next Steps
- Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
- The company will file a proxy statement and WHITE proxy card with the SEC.
- The company will hold its 2025 Annual Meeting of Stockholders on May 28, 2025.
Key Dates
| Date | Description |
|---|---|
| April 8, 2025 | Record date for determining stockholders entitled to notice of and to vote at the Annual Meeting. |
| April 15, 2025 | Date of the notice of annual meeting and proxy statement. |
| May 27, 2025 | Deadline for telephone and Internet voting for stockholders of record (11:59 p.m. Eastern Time). |
| May 28, 2025 | Date and time of the Annual Meeting of Stockholders (11:00 a.m. Eastern Time). |
| December 26, 2025 | Deadline for stockholders to submit proposals for inclusion in the proxy materials for the 2026 Annual Meeting. |
| January 28, 2026 | Earliest date for stockholders to submit proposals or director nominations for the 2026 Annual Meeting (outside of proxy statement). |
| February 27, 2026 | Latest date for stockholders to submit proposals or director nominations for the 2026 Annual Meeting (outside of proxy statement). |
| March 30, 2026 | Deadline for stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees to comply with the additional requirements of Rule 14a-19 of the Exchange Act, including sending notice. |
Keywords
annual meeting, proxy statement, stockholders, directors, executive compensation, Deloitte & Touche, officer exculpation, corporate governance, Precision BioSciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.